Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

429 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy.
Chiricozzi A, Di Nardo L, Talamonti M, Galluzzo M, De Simone C, Fabbrocini G, Marzano AV, Girolomoni G, Offidani A, Rossi MT, Bianchi L, Cristaudo A, Fierro MT, Stingeni L, Pellacani G, Argenziano G, Patrizi A, Pigatto P, Romanelli M, Savoia P, Rubegni P, Foti C, Milanesi N, Belloni Fortina A, Bongiorno MR, Grieco T, Di Nuzzo S, Fargnoli MC, Carugno A, Motolese A, Rongioletti F, Amerio P, Balestri R, Potenza C, Micali G, Patruno C, Zalaudek I, Lombardo M, Feliciani C, Antonelli F, Ferrucci SM, Guarneri F, Peris K. Chiricozzi A, et al. Among authors: offidani a. Dermatitis. 2022 May-Jun 01;33(3):e25-e29. doi: 10.1097/DER.0000000000000814. Epub 2021 Dec 10. Dermatitis. 2022. PMID: 35129461 Free PMC article. No abstract available.
Omalizumab in Chronic Urticaria: An Italian Survey.
Damiani G, Diani M, Conic RRZ, Colli L, Ferrucci S, Martina E, Offidani AM, Pigatto PDM. Damiani G, et al. Int Arch Allergy Immunol. 2019;178(1):45-49. doi: 10.1159/000492532. Epub 2018 Nov 5. Int Arch Allergy Immunol. 2019. PMID: 30396176
Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
Marzano AV, Genovese G, Casazza G, Fierro MT, Dapavo P, Crimi N, Ferrucci S, Pepe P, Liberati S, Pigatto PD, Offidani A, Martina E, Girolomoni G, Rovaris M, Foti C, Stingeni L, Cristaudo A, Canonica GW, Nettis E, Asero R. Marzano AV, et al. Among authors: offidani a. J Eur Acad Dermatol Venereol. 2019 May;33(5):918-924. doi: 10.1111/jdv.15350. Epub 2018 Dec 7. J Eur Acad Dermatol Venereol. 2019. PMID: 30451325 Free article.
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study.
Papini M, Cusano F, Romanelli M, Burlando M, Stinco G, Girolomoni G, Peris K, Potenza C, Offidani A, Bartezaghi M, Aloisi E, Costanzo A; SUPREME study group. Papini M, et al. Among authors: offidani a. Br J Dermatol. 2019 Aug;181(2):413-414. doi: 10.1111/bjd.18013. Epub 2019 May 29. Br J Dermatol. 2019. PMID: 31001812 Clinical Trial. No abstract available.
429 results